Vol. 3 No. 3 (2025)
30 September 2025
May 1 marked the release of the #iCARDIO Guidelines on Heart Failure, now live in Global Cardiology. This global-first effort brings flexible, practical guidance to frontline providers managing #heartfailure in any setting. www.globalcardiology.info/site/article... #GlobalHealth #cardiosky
— iCardio (@icardio.bsky.social) May 13, 2025 at 8:26
[image or embed]
Impaired energy metabolism contributed to clinical severity, disease progression and to outcome in heart failure (HF). Insulin sensitivity (IS) is a key metabolic factor in the control of energy substrate utilisation and energy efficiency in cardiac and skeletal muscle. Impaired IS, or insulin resistance, is a common finding in HF and has been shown to predict morbidity and mortality in patients with heart failure with reduced and mildly reduced ejection fraction (HFrEF, HFmrEF). Despite its pathophysiologic relevance, IS has not been...
Aldosterone plays a pivotal role in the progression of cardio-renal diseases by driving myocardial fibrosis, vascular dysfunction, and renal injury through both genomic and non-genomic mechanisms. While mineralocorticoid receptor antagonists have long served as the cornerstone of pharmacologic intervention, their use is limited by adverse effects such as hyperkalemia, gynecomastia, and incomplete suppression of aldosterone-mediated pathology. Aldosterone synthase inhibitors, a novel class of therapeutics, offer a promising alternative by...
